By the comprehensive analysis of tumor–immune system interactions, we found that the difference in UNC5B expression was significant in urothelial carcinoma and melanoma immunotherapy, and the difference in NTN1 expression was also significant in melanoma immunotherapy. This evidence concerns the gene UNC5B and melanoma.